• Mashup Score: 4

    Asthma is a chronic disease of airway inflammation and airway hyperresponsiveness due to smooth muscle hyperreactivity, complicated by exacerbations leading to significant morbidity and mortality. Despite major advances in pharmacotherapy, therapeutic options for the smooth muscle are lacking and many patients remain uncontrolled.1 Bronchial thermoplasty (BT) is a nonpharmacologic treatment of severe asthma in which thermal energy is applied to the airway walls to decrease smooth muscle mass and the effects of airway hyperreactivity.

    Tweet Tweets with this article
    • In Current Issue (FREE)! #Bronchial #Thermoplasty in the #Biologic Era https://t.co/HiFZlRLmRq

  • Mashup Score: 0

    To the Editor: The long-term treatment of psoriasis with biologics is associated with a gradual decrease of efficacy, leading to treatment discontinuation in a significant proportion of patients.1-3 As such, prognostic tools might be useful in optimizing long-term outcomes of biologic treatment. In this study, we compared the accuracy of a traditional statistical risk factor-based model versus machine learning (ML) in predicting the 5-year probability of biologic drug discontinuation.

    Tweet Tweets with this article
    • In this JAAD study, authors compared the accuracy of a traditional statistical risk factor-based model versus #machinelearning (ML) in predicting the 5-year probability of #biologic drug discontinuation. https://t.co/MzUDTyGxLk https://t.co/DEmcCKxlYG

  • Mashup Score: 3

    The availability of biologic agents for patients with severe asthma has increased dramatically over the last several decades. The absence of direct head-to-head comparative data and relative lack of biomarkers to predict response can make it difficult to choose the right biologic medication for a given patient. Selecting a biologic agent for the pediatric population presents further challenges due to more limited approved biologic agents and fewer clinical trials in children. In addition, the outcome data that are currently available suggest that treatment responses for a given biologic may be different between adult and pediatric patients.

    Tweet Tweets with this article
    • In Press! #Controversies in #Allergy: Are #Biologic #Treatment #Responses in #Severe #Asthma the Same in #Adults and #Children? https://t.co/zLhlpkLQgn https://t.co/MeP7VrK23L

  • Mashup Score: 0

    Using publicly available data from review documents on Drugs@FDA, Friends created this dashboard to show how four expedited programs impact the time it takes for a drug or biologic to be approved. This dashboard displays data on original therapeutic agents approved for use in oncology since January 2013 when the most recent expedited pathway, Breakthrough…

    Tweet Tweets with this article
    • Using publicly available data from review documents on Drugs@FDA, Friends created a dashboard to show how four FDA expedited programs impact the time it takes for a #drug or #biologic to be approved. Click here to utilize this great resource: https://t.co/6ZZhDl3sE8 https://t.co/YCP7DCFKCN

  • Mashup Score: 0

    The recent success of chimeric antigen receptor-T cell therapy, along with three high-profile FDA approvals, may help make precision medicine a reality in lupus, according to a presenter at the Biologic Therapies Summit.“It is prime time for biologic therapies and the treatment of lupus,” Emily Littlejohn, DO, MPH, of the department of rheumatologic and immunologic disease at the

    Tweet Tweets with this article
    • “It is prime time for #biologic therapies and the treatment of #lupus,” Emily Littlejohn, DO, MPH (@ELittlejohnDO), told attendees #RheumTwitter https://t.co/T70gz8DtcR

  • Mashup Score: 0

    Biologic therapy persistence in psoriatic arthritis often depends on whether the drug was a first or second treatment, with depression, anxiety, older age and higher tender joint count also leading to discontinuation, according to data.“The development of new biological disease-modifying antirheumatic drugs (bDMARDs) for PsA has led to better disease control as well as slowing of

    Tweet Tweets with this article
    • ICYMI: #Biologic therapy persistence in psoriatic #arthritis often depends on whether the drug was a first or second treatment, with depression, anxiety, older age and higher tender joint count also leading to discontinuation @MohamadAliTRida https://t.co/AflFbRwA9F

  • Mashup Score: 0

    Biologic therapy persistence in psoriatic arthritis often depends on whether the drug was a first or second treatment, with depression, anxiety, older age and higher tender joint count also leading to discontinuation, according to data.“The development of new biological disease-modifying antirheumatic drugs (bDMARDs) for PsA has led to better disease control as well as slowing of

    Tweet Tweets with this article
    • #Biologic therapy persistence in psoriatic #arthritis often depends on whether the drug was a first or second treatment, with depression, anxiety, older age and higher tender joint count also leading to discontinuation @MohamadAliTRida https://t.co/AflFbRwA9F

  • Mashup Score: 11

    Sarilumab offers a new treatment option for PMR, reducing reliance on corticosteroids. Learn about the benefits and risks.

    Tweet Tweets with this article
    • ‼️FDA approves Sarilumab for polymyalgia rheumatica‼️ This is the first #biologic drug approved for polymyalgia rheumatica (PMR), and it can offer new hope to people who were previously only treated with corticosteroids. https://t.co/hu2kldG6bT